April 13, 2021 - Global Reach Health, committed to giving back to the community and beyond, hosted a donation drive this past week, for necessary supplies needed in Guatemala.
April 7, 2021 – The U.S. FDA has granted full approval for Trodelvy® (sacituzumab govitecan-hziy), manufactured by Gilead, to treat unresectable locally
April 6, 2021 – The U.S. FDA has approved a new dosing regimen for Erbitux® (cetuximab), manufactured by ImClone. The drug may now be administered once every two weeks to treat
April 2, 2021 – The U.S. FDA has approved Qelbree® (viloxazine) extended-release oral capsules, manufactured by Supernus Pharmaceuticals, to treat attention
April 1, 2021 – The U.S. FDA has approved a new indication for Tyvaso® (treprostinil), manufactured by United Therapeutics, to treat patients who have pulmonary